Cystic fibrosis in Europe: improved lung function & longevity: reasons for cautious optimism, but challenges remain.
Journal
The European respiratory journal
ISSN: 1399-3003
Titre abrégé: Eur Respir J
Pays: England
ID NLM: 8803460
Informations de publication
Date de publication:
01 Feb 2024
01 Feb 2024
Historique:
received:
25
07
2023
accepted:
08
01
2024
medline:
2
2
2024
pubmed:
2
2
2024
entrez:
1
2
2024
Statut:
aheadofprint
Résumé
Prognosis and disease severity in cystic fibrosis (CF) is linked to declining lung function. To characterize lung function by the number of adults in countries with different level of Gross National Income (GNI), data from the European Cystic Fibrosis Society Patient Registry was utilized. Annual data including age, forced expiratory volume in 1 s (FEV A consistent improvement in FEV This pan-European analysis demonstrates a consistent improvement in FEV
Sections du résumé
BACKGROUND
BACKGROUND
Prognosis and disease severity in cystic fibrosis (CF) is linked to declining lung function. To characterize lung function by the number of adults in countries with different level of Gross National Income (GNI), data from the European Cystic Fibrosis Society Patient Registry was utilized.
METHODS
METHODS
Annual data including age, forced expiratory volume in 1 s (FEV
FINDINGS
RESULTS
A consistent improvement in FEV
INTERPRETATION
CONCLUSIONS
This pan-European analysis demonstrates a consistent improvement in FEV
Identifiants
pubmed: 38302155
pii: 13993003.01241-2023
doi: 10.1183/13993003.01241-2023
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright ©The authors 2024. For reproduction rights and permissions contact permissions@ersnet.org.